BioInvent (BOVNF) Appoints Head Of Clinical Development

BioInvent International AB (STO:BINV) today announced that Anna Wickenberg has been appointed as Vice President Clinical Development, responsible for the clinical development of BioInvent's drug development projects. She will be part of the Management group and reports to the CEO.

Suggested Articles

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.